To validate the clinical relevance of ZEB1 in prostate cancer in response to docetaxel treatment, IHC staining of ZEB1 expression was performed in a TMA comprising tumour tissue specimens from 27 Gleason score and aged‐matched patients with prostate cancer; 14 of whom received docetaxel therapy prior to radical prostatectomy. The gene discussed is ZEB1; the disease is prostate carcinoma.